Man Group plc Makes New $3.02 Million Investment in Celcuity, Inc. $CELC

Key Points

• Man Group acquired 28,845 Celcuity shares worth approximately $3.02 million in the second quarter, giving it about 0.06% of the company. Institutional investors and hedge funds collectively own 63.33% of CELC.
• Celcuity reported a quarterly loss of $1.44 per share, missing the $1.16 consensus estimate; analysts expect a full-year loss of $4.75 per share.
• Analyst sentiment remains broadly positive, with 10 Buy ratings and one Sell rating, a “Moderate Buy” consensus, and an average price target of $154.55 versus the stock’s $89.06 opening price.

Man Group plc acquired a new stake in Celcuity, Inc. (NASDAQ:CELC - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 28,845 shares of the company's stock, valued at approximately $3,018,000. Man Group plc owned approximately 0.06% of Celcuity as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Avoro Capital Advisors LLC acquired a new stake in Celcuity during the fourth quarter valued at approximately $310,302,000. NEA Management Company LLC boosted its stake in Celcuity by 64.9% in the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company's stock valued at $352,637,000 after buying an additional 1,391,300 shares in the last quarter. State Street Corp grew its position in Celcuity by 126.6% in the fourth quarter. State Street Corp now owns 1,637,687 shares of the company's stock valued at $163,343,000 after acquiring an additional 914,887 shares during the period. UBS Group AG raised its stake in Celcuity by 910.1% during the third quarter. UBS Group AG now owns 854,483 shares of the company's stock worth $42,211,000 after acquiring an additional 769,891 shares in the last quarter. Finally, Deerfield Management Company L.P. acquired a new position in Celcuity during the third quarter worth $36,236,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Stock Up 0.7%

Shares of CELC opened at $89.06 on Tuesday. The firm has a market capitalization of $4.36 billion, a price-to-earnings ratio of -20.71 and a beta of 0.21. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. The business's fifty day moving average price is $94.62 and its two-hundred day moving average price is $107.04. Celcuity, Inc. has a 52 week low of $44.42 and a 52 week high of $151.02.

Celcuity (NASDAQ:CELC - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.28). On average, analysts predict that Celcuity, Inc. will post -4.75 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on CELC. Citigroup reaffirmed a "market outperform" rating on shares of Celcuity in a report on Monday, August 17th. Citizens Jmp reaffirmed a "market outperform" rating and set a $177.00 price objective on shares of Celcuity in a report on Monday, August 17th. Wells Fargo & Company reduced their target price on Celcuity from $183.00 to $166.00 and set an "overweight" rating on the stock in a report on Wednesday, June 3rd. Guggenheim raised their price target on Celcuity from $165.00 to $175.00 and gave the company a "buy" rating in a report on Monday, August 17th. Finally, Weiss Ratings upgraded Celcuity from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, June 4th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Celcuity presently has a consensus rating of "Moderate Buy" and an average target price of $154.55.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source